336 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Diversify Advisory Services LLC

Diversify Advisory Services LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 336 shares of the biopharmaceutical company’s stock, valued at approximately $234,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $37,000. Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $49,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on REGN. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Bank of America reiterated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Stock Up 2.1 %

NASDAQ:REGN opened at $694.64 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The firm has a market capitalization of $76.33 billion, a price-to-earnings ratio of 17.19, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average price is $730.57 and its two-hundred day moving average price is $942.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.